Intermittent PPI regimens are comparable to continuous PPI infusion regimens in patients with bleeding ulcers and high-risk endoscopic findings. Given the greater ease of use and lower cost and resource utilization, intermittent PPI therapy should be the regimen of choice after endoscopic therapy in such patients.

IV PPI is indicated in the treatment of high-risk peptic ulcers, complicated gastroesophageal reflux, stress-induced ulcer prophylaxis, Zollinger–Ellison syndrome, and whenever it is impossible or impractical to give oral therapy. The widespread use of PPIs has been controversial.

Intermittent PPI therapy is comparable to the current guideline-recommended regimen of intravenous bolus plus a continuous infusion of PPIs in patients with endoscopically treated high-risk bleeding ulcers. Guidelines should be revised to recommend intermittent PPI therapy.

May 31, 2024 · Proton pump inhibitors (PPIs) effectively block gastric acid secretion by irreversibly binding to and inhibiting the hydrogen-potassium ATPase pump that resides on the …

Compared to placebo, a proton pump inhibitor (PPI) bolus followed by continuous infusion maintained a pH below 6; thus, this regimen was historically utilized in patients with a GIB [3].

Background: Proton pump inhibitor (PPI) continuous infusions or intermittent boluses are used for the treatment of upper gastrointestinal bleeding (UGIB). Intermittent boluses are easier to give and are of lower cost without affecting clinical outcomes.

Our findings support the potential benefit of PPI therapy for reducing PND frequency, hoarseness, and chronic cough, and confirm a placebo effect for other laryngopharyngeal reflux symptoms.

May 1, 2023 · Proton pump inhibitors represent a class of medications used to treat a wide variety of pathologies related to the stomach's acid production. This activity reviews the indications, action, contraindications for proton pump inhibitors as …

Intermittent PPI therapy is comparable to the current guideline-recommended regimen of intravenous bolus plus a continuous infusion of PPIs in patients with endoscopically treated high-risk bleeding ulcers. Guidelines should be revised to recommend intermittent PPI therapy.

In the post-endoscopy setting, PPIs via continuous infusion (PPI drip) for 72 hours in patients who have ulcers with high-risk stigmata reduce the rates of rebleeding, surgery, and mortality.